• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Cue Biopharma Inc.

    11/18/22 4:04:10 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CUE alert in real time by email
    SC 13G 1 sc13g13606cue_11182022.htm

     UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

    (Amendment No. )1

     

    Cue Biopharma, Inc.

     (Name of Issuer)

    Common Stock, par value $0.001 per share

     (Title of Class of Securities)

    22978P106

     (CUSIP Number)

    November 16, 2022

     (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

       ☐  Rule 13d-1(b)

       ☒  Rule 13d-1(c)

       ☐  Rule 13d-1(d)

     

     

     

    1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 22978P106

     

      1   NAME OF REPORTING PERSON  
             
            Slate Path Master Fund LP  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Cayman Islands  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         2,402,455  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         - 0 -  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              2,402,455  
        8   SHARED DISPOSITIVE POWER  
               
              - 0 -  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            2,402,455  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            5.6%  
      12   TYPE OF REPORTING PERSON  
             
            PN  

      

    2

    CUSIP No. 22978P106

      1   NAME OF REPORTING PERSON  
             
            Slate Path Capital LP  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         2,402,455  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         - 0 -  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              2,402,455  
        8   SHARED DISPOSITIVE POWER  
               
              - 0 -  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            2,402,455  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            5.6%  
      12   TYPE OF REPORTING PERSON  
             
            IA  

      

    3

    CUSIP No. 22978P106

     

      1   NAME OF REPORTING PERSON  
             
            Jades GP, LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         2,402,455  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         - 0 -  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              2,402,455  
        8   SHARED DISPOSITIVE POWER  
               
              - 0 -  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            2,402,455  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            5.6%  
      12   TYPE OF REPORTING PERSON  
             
            OO  

      

    4

    CUSIP No. 22978P106

     

      1   NAME OF REPORTING PERSON  
             
            David Greenspan  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            United States  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         2,402,455  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         - 0 -  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              2,402,455  
        8   SHARED DISPOSITIVE POWER  
               
              - 0 -  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            2,402,455  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            5.6%  
      12   TYPE OF REPORTING PERSON  
             
            IN  

      

    5

    CUSIP No. 22978P106

    Item 1(a).Name of Issuer:

     

    Cue Biopharma, Inc., a Delaware corporation (the “Issuer”).

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    40 Guest Street

    Boston, Massachusetts 02135

     

    Item 2(a).Name of Person Filing
    Item 2(b).Address of Principal Business Office or, if None, Residence
    Item 2(c).Citizenship

     

    Slate Path Master Fund LP (the “Master Fund”)

    Ugland House

    121 South Church Street

    George Town, Cayman Islands KY1-1104

    Citizenship: Cayman Islands

     

    Slate Path Capital LP (“Slate Path”)

    717 Fifth Avenue, 16th Floor

    New York, New York 10022

    Citizenship: Delaware

     

    Jades GP, LLC (“Jades”)

    717 Fifth Avenue, 16th Floor

    New York, New York 10022

    Citizenship: Delaware

     

    David Greenspan (“Mr. Greenspan”)

    717 Fifth Avenue, 16th Floor

    New York, New York 10022

    Citizenship: United States

     

    Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.”

     

    Item 2(d).Title of Class of Securities:

     

    Common Stock, par value $0.001 per share (the “Shares”).

     

    Item 2(e).CUSIP Number:

     

    22978P106

     

    6

    CUSIP No. 22978P106

    Item 3.If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

     

        /x/ Not applicable.
           
      (a) / / Broker or dealer registered under Section 15 of the Exchange Act.
           
      (b) / / Bank as defined in Section 3(a)(6) of the Exchange Act.
           
      (c) / / Insurance company as defined in Section 3(a)(19) of the Exchange Act.
           
      (d) / / Investment company registered under Section 8 of the Investment Company Act.
           
      (e) / / An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
           
      (f) / / An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
           
      (g) / / A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
           
      (h) / / A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
           
      (i) / / A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.
           
      (j) / / A non-U.S. institution, in accordance with Rule 13d-1(b)(1)(ii)(J).
           
      (k) / / Group, in accordance with Rule 13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

    Item 4.Ownership

     

    (a)Amount beneficially owned:

     

    As of the close of business on November 18, 2022, the Master Fund beneficially owned 2,402,455 Shares.

     

    Each of (i) Slate Path, as the investment manager of the Master Fund, (ii) Jades, as the general partner of Slate Path, and (iii) Mr. Greenspan, as the managing partner of Jades, may be deemed to beneficially own the Shares owned by the Master Fund.

     

    Each Reporting Person, as a member of a “group” with the other Reporting Persons for the purposes of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, may be deemed the beneficial owner of the Shares directly owned by the other Reporting Persons. Each Reporting Person disclaims beneficial ownership of such Shares except to the extent of his or its pecuniary interest therein. The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any Shares owned by another Reporting Person.

     

    7

    CUSIP No. 22978P106

    (b)Percent of class:

     

    The following percentages are based on 43,042,548 Shares outstanding as of November 16, 2022, which is the total number of Shares outstanding following the close of the Issuer’s offering disclosed in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 15, 2022.

     

    As of the close of business on November 18, 2022, the Master Fund beneficially owned approximately 5.6% of the outstanding Shares and each of Slate Path, Jades and Mr. Greenspan, by virtue of their relationships described above, may be deemed to beneficially own approximately 5.6% of the outstanding Shares.

     

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or to direct the vote

     

    See Cover Pages Items 5-9.

     

    (ii)Shared power to vote or to direct the vote

     

    See Cover Pages Items 5-9.

     

    (iii)Sole power to dispose or to direct the disposition of

     

    See Cover Pages Items 5-9.

     

    (iv)Shared power to dispose or to direct the disposition of

     

    See Cover Pages Items 5-9.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    Not applicable.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    See Exhibit 99.1.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    8

    CUSIP No. 22978P106

    Item 10.Certifications.

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    9

    CUSIP No. 22978P106

    SIGNATURE

     

    After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: November 18, 2022

      SLATE PATH MASTER FUND LP
       
      By: Slate Path Capital LP, its investment manager
         
      By: Jades GP, LLC, its general partner
         
      By:

    /s/ John Metzner

        Name: John Metzner
        Title: Chief Operating Officer

     

     

      SLATE PATH CAPITAL LP
       
      By: Jades GP, LLC, its general partner
         
      By:

    /s/ John Metzner

        Name: John Metzner
        Title: Chief Operating Officer

     

     

      JADES GP, LLC
       
      By:

    /s/ John Metzner

        Name: John Metzner
        Title: Chief Operating Officer

     

     

     

    /s/ David Greenspan

      DAVID GREENSPAN

     

    10

    Get the next $CUE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CUE

    DatePrice TargetRatingAnalyst
    3/13/2024$6.00Buy
    Jefferies
    6/26/2023$10.00Outperform
    Oppenheimer
    11/21/2022$7.00Overweight
    Piper Sandler
    1/13/2022$20.00Buy
    H.C. Wainwright
    1/3/2022$28.00Buy
    Craig Hallum
    More analyst ratings

    $CUE
    SEC Filings

    View All

    SEC Form S-8 filed by Cue Biopharma Inc.

    S-8 - Cue Biopharma, Inc. (0001645460) (Filer)

    8/12/25 4:11:48 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Cue Biopharma Inc.

    10-Q - Cue Biopharma, Inc. (0001645460) (Filer)

    8/12/25 4:00:53 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cue Biopharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Cue Biopharma, Inc. (0001645460) (Filer)

    8/12/25 4:00:29 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CUE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Broadfoot Jill Marie

    4 - Cue Biopharma, Inc. (0001645460) (Issuer)

    6/6/25 4:00:05 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Broadfoot Jill Marie

    3 - Cue Biopharma, Inc. (0001645460) (Issuer)

    6/6/25 4:00:04 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CHIEF FINANCIAL OFFICER Millar Kerri-Ann

    4 - Cue Biopharma, Inc. (0001645460) (Issuer)

    3/25/25 4:00:10 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CUE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies initiated coverage on Cue Biopharma with a new price target

    Jefferies initiated coverage of Cue Biopharma with a rating of Buy and set a new price target of $6.00

    3/13/24 7:30:48 AM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer resumed coverage on Cue Biopharma with a new price target

    Oppenheimer resumed coverage of Cue Biopharma with a rating of Outperform and set a new price target of $10.00

    6/26/23 7:24:09 AM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Cue Biopharma with a new price target

    Piper Sandler initiated coverage of Cue Biopharma with a rating of Overweight and set a new price target of $7.00

    11/21/22 7:39:31 AM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CUE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare Conference

    BOSTON, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, today announced that it will participate in a fireside chat at the Cantor Global Healthcare Conference being held in New York, September 3-5, 2025. During the fireside chat, Cue Biopharma will discuss program updates from the Immuno-STAT® platform including continued advancements in the development of CUE-401, the Company's lead autoimmune asset. Presentation DetailsCantor Global Healthcare Conference Date: Frid

    8/21/25 8:00:00 AM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme

    First patient dosed with CUE-102 for recurrent glioblastoma multiforme (rGBM) at Dana-Farber Cancer Institute (DFCI) BOSTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, announced today the initiation of an investigator sponsored trial (IST) in rGBM at the DFCI with the first patient in the trial having been dosed with CUE-102. The trial (NCT06917885) is a Phase 1b, open-label study of adjuvant CUE-102, the Company's drug product candidate targeting Wilms' Tumor 1

    8/13/25 8:00:00 AM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights

    Received FDA feedback on Pre-IND Briefing Document reinforcing Company's intention to advance investigational new drug (IND) submission for CUE-401 to address unmet need in the treatment of autoimmune disease. Announced strategic research collaboration and license agreement with Boehringer Ingelheim to develop and commercialize CUE-501, a differentiated B cell depletion therapy for autoimmune and inflammatory diseases. Upfront payment of $12 million and ~$345 million in potential milestone payments Raised approximately $20 million through a public offering. BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage bio

    8/12/25 4:05:00 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CUE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF EXECUTIVE OFFICER Passeri Daniel R bought $30,900 worth of shares (30,000 units at $1.03), increasing direct ownership by 22% to 164,578 units (SEC Form 4)

    4 - Cue Biopharma, Inc. (0001645460) (Issuer)

    12/18/24 4:00:04 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CUE
    Leadership Updates

    Live Leadership Updates

    View All

    Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer

    BOSTON, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced the appointment of industry veteran Lucinda Warren as chief business officer (CBO). With an extensive background and proven expertise in strategic transactions, portfolio optimization and alliance management through her extensive tenure at Johnson & Johnson and Jansen, Ms. Warren will play a pivotal role in advancing Cue Biopharma's core corporate objectives following the company's recent business restructuring and autoimmune program prioritizati

    9/9/24 8:00:00 AM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cue Biopharma Welcomes Seasoned Pharmaceutical Executive Pamela D. Garzone, Ph.D., to its Board of Directors

    BOSTON, April 25, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body, announced today the appointment of seasoned pharmaceutical executive Pamela D. Garzone, Ph.D., to its board of directors. Dr. Garzone brings to Cue Biopharma more than 25 years of healthcare and pharmaceutical industry experience in drug development, including strategic, scientific, clinical and regulatory leadership expertise. "We are pleased to have Dr. Garzone join our board of directors," said Daniel Passeri, chief executive

    4/25/23 8:00:00 AM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cue Biopharma Welcomes Industry Veteran Mr. Patrick Verheyen to its Board of Directors

    BOSTON, April 12, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body, announced today the appointment of industry veteran Patrick Verheyen to its board of directors (BOD). Mr. Verheyen brings to Cue Biopharma more than 35-years of experience facilitating pipeline growth and innovation programs at Janssen Pharmaceutical Companies of Johnson and Johnson. "We are very pleased to welcome Mr. Verheyen to our BOD and leverage his extensive experience and guidance as we seek to enhance and broaden Cue Bi

    4/12/23 8:00:00 AM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CUE
    Financials

    Live finance-specific insights

    View All

    Cue Biopharma to Host Business Update Call and Webcast

    BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announced that it will host a conference call and webcast to provide a business update on Tuesday, April 15, 2025 at 4:30 p.m. ET. Conference Call and Webcast DetailsTuesday, April 15 at 4:30 p.m. ET Investors:1-844-826-3035International Investors:1-412-317-5195Conference ID:10199037Webcast Link:https://viavid.webcasts.com/starthere.jsp?ei=1715808&tp_key=9378826572 The live and archived webcast will also b

    4/14/25 5:02:00 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cue Biopharma to Host Business Update Call and Webcast

    BOSTON, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, announced today that it will host a conference call and webcast to provide a business update on Monday, August 19, 2024 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company's website. The company will provide a business overview of its recent restructuring and near-term strategic prioritization objectives. The discussion will focus on the company's approach to enhance near-term shareholder value by refocusing resourc

    8/13/24 8:00:00 AM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cue Biopharma to Host Business Update Call and Webcast

    BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will host a conference call and webcast to provide a business update on Monday, April 8, 2024 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company's website. The Company will provide a corporate update highlighting measurable progress advancing its lead clinical oncology programs, CUE-101 and CUE-102, its lead preclinical autoimmune program CUE-401 partnered with Ono Pharmaceutical, as well as additional au

    4/2/24 8:00:00 AM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CUE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Cue Biopharma Inc.

    SC 13G - Cue Biopharma, Inc. (0001645460) (Subject)

    3/11/24 6:40:41 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Cue Biopharma Inc.

    SC 13G - Cue Biopharma, Inc. (0001645460) (Subject)

    2/7/24 5:09:04 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Cue Biopharma Inc.

    SC 13G - Cue Biopharma, Inc. (0001645460) (Subject)

    1/31/24 2:08:28 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care